| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 1g |
|
||
| Other Sizes |
|
Purity: ≥98%
Asiatic acid (Dammarolic acid, Asiantic acid) is a pentacyclic triterpene that naturally occurs in a variety of plants, including the plant C. asiatica. It is also an aglycone of the asiaticoside. This pentacyclic triterpene is frequently used to treat wounds and may have anti-inflammatory properties. Asiatic acid not only reduces inflammation but also promotes the production of collagen, which speeds up the healing process after wounds. Breast cancer cells have been shown to undergo apoptosis and cell cycle arrest when exposed to it. Furthermore, it lessens the cognitive deficits and neuronal damage brought on by mice receiving glutamate in vivo. in Centella asiatica, a pentacyclic triterpene.
| Targets |
p38 MAPK
|
||
|---|---|---|---|
| ln Vitro |
Two human breast cancer cell lines were exposed to asiatic acid, which inhibited cell growth in a concentration-dependent manner, with MCF-7 being more susceptible than MDA-MB-231. For MCF-7 and MDA-MB-231, asiatic acid's IC50 values were 5.95 M and 8.12 M, respectively.
|
||
| ln Vivo |
|
||
| Enzyme Assay |
ERK1/2 and p38 MAPK Kinase Activity Assays, as well as Immunoprecipitation/Immunoblot. When MAPK inhibitors were present or absent, cells were exposed to 10 μM asiatic acid for the allotted amount of time. Apoptosis assay kit made by BioVision Inc., Mountain View, California, was used to separate the mitochondrial and cytoplasmic fractions. In order to prepare the cells for immunoblotting, they were lysed on ice for 40 minutes in a solution containing 50 mM Tris, 1% Triton X-100, 0.1% SDS, 150 mM NaCl, 2 mM Na3VO4, 2 mM EGTA, 12 mM β-glycerol phosphate, 10 mM NaF, and 16 μg/ml benzamidine hydrochloride, 10 μg/ml phenanthroline, 10 μg/ml aprotinin, 10 μg/ml leupeptin, 10 μg/ml pepstatin, and 1 mM phenylmethylsulfonyl fluoride. The supernatant fraction from the 15-minute 14,000g centrifugation of the cell lysate was used for immunoblotting. SDS-polyacrylamide gel electrophoresis was used to resolve equivalent amounts of protein (10–12%), which were then transferred to polyvinylidene difluoride membranes. The membrane was incubated with the desired primary antibody for 1 to 16 hours after blocking for 1 h in 5% nonfat dry milk in Tris-buffered saline. After applying the proper peroxidase-conjugated secondary antibody to the membrane, as directed by the manufacturer, the immunoreactive proteins were found using an enhanced chemiluminescence kit from Amersham Biosciences Inc., Piscataway, NJ.
|
||
| Cell Assay |
The sodium 3′-[1-(phenylamino-carbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-nitro)benzene-sulfonic acid hydrate (XTT) assay was used to determine how much asiatic acid inhibited cell proliferation. In 96-well culture plates, cells were plated at a density of 1 × 104 per well. The cells were exposed to asiatic acid (0, 2.5, 5, 10, and 20 μM) for 48 hours after a 24-hour incubation period. Each well was then filled with 50 microliters of the XTT test solution, which was created by combining 5 ml of the XTT-labeling reagent with 100 μl of the electron coupling reagent. At a test wavelength of 492 nm and a reference wavelength of 690 nm, absorbance was measured using an ELISA reader (Multiskan EX; Labsystem, Helsinki, Finland) after a 4-h incubation. The formula inhibition % = [100 - (ODt/ODs) × 100] was used to calculate data as the percentage of inhibition. The optical densities of the test substances and the solvent control were indicated, respectively, by ODt and ODs. Based on 48-h absorbance values, the concentration of test substances that cause 50% cellular cytotoxicity of cancer cells (IC50) was determined.
|
||
| Animal Protocol |
|
||
| References |
| Molecular Formula |
C30H48O5
|
|
|---|---|---|
| Molecular Weight |
488.70
|
|
| Exact Mass |
488.35
|
|
| Elemental Analysis |
C, 73.73; H, 9.90; O, 16.37
|
|
| CAS # |
464-92-6
|
|
| Related CAS # |
|
|
| Appearance |
Solid powder
|
|
| SMILES |
C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(C[C@H]([C@@H]([C@@]5(C)CO)O)O)C)C)[C@@H]2[C@H]1C)C)C(=O)O
|
|
| InChi Key |
JXSVIVRDWWRQRT-UYDOISQJSA-N
|
|
| InChi Code |
InChI=1S/C30H48O5/c1-17-9-12-30(25(34)35)14-13-28(5)19(23(30)18(17)2)7-8-22-26(3)15-20(32)24(33)27(4,16-31)21(26)10-11-29(22,28)6/h7,17-18,20-24,31-33H,8-16H2,1-6H3,(H,34,35)/t17-,18+,20-,21-,22-,23+,24+,26+,27+,28-,29-,30+/m1/s1
|
|
| Chemical Name |
(1S,2R,4aS,6aR,6aS,6bR,8aR,9R,10R,11R,12aR,14bS)-10,11-dihydroxy-9-(hydroxymethyl)-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-4a-carboxylic acid
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.25 mg/mL (4.60 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 22.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.08 mg/mL (4.26 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.26 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0462 mL | 10.2312 mL | 20.4625 mL | |
| 5 mM | 0.4092 mL | 2.0462 mL | 4.0925 mL | |
| 10 mM | 0.2046 mL | 1.0231 mL | 2.0462 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA